SCHEMBL20370513

SCHEMBL20370513

C=CC(=O)N(C)C1CCC(c2ccc(-c3ccc(C4CCC(CCCCC)CC4)cc3)c(CC)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.36
▸ SPHK1 Q9NYA1 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ FASN P49327 1/20 0.35
▸ LSS P48449 3/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.33
▸ P2RY14 Q15391 1/20 0.33
▸ DGAT1 O75907 2/20 0.32
▸ SOAT1 P35610 1/20 0.32
▸ BTK Q06187 3/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ESR2 Q92731 1/20 0.31
▸ APP P05067 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20370510 0.91 CYP2C9 (0.36) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL20370509 0.90 FASN (0.45) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL20370511 0.90 FASN (0.45) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL20370512 0.90 CYP2C9 (0.37) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL20370504 0.89 CYP2C9 (0.43) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL19854467 0.88 CYP2C9 (0.45) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL19854990 0.86 CYP2C9 (0.37) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL19854093 0.85 CYP2C9 (0.43) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL19853832 0.85 CYP2C9 (0.43) CYP2C9SPHK1ALDH1A1LMNAMAPT
SCHEMBL19853836 0.85 CYP2C9 (0.34) CYP2C9SPHK1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2020-05-26 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, MBD2, PAXBP1 CYP2C9 3761/4885SPHK1 906/4885ALDH1A1 3826/4885
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device SP1, MBD2, PAXBP1 CYP2C9 3761/4885SPHK1 906/4885ALDH1A1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback